William Meury has sold stock and made no open-market buys since Dec 2017

William (Bill) Meury is a biopharmaceutical executive and former independent director of Syndax Pharmaceuticals Inc. (SNDX), where he served on the board from 2018 until his resignation in June 2025.( His departure from Syndax’s board was prompted by his acceptance of the roles of President, Chief Executive Officer, and board member at Incyte Corporation, a key collaboration partner of Syndax, and was not related to any disagreement over Syndax’s operations, policies, or practices.(

Meury has more than three decades of experience in the life sciences industry, including senior leadership roles as CEO of Incyte, CEO of Anthos Therapeutics, President and CEO of Karuna Therapeutics, Partner at Hildred Capital Management, and Chief Commercial Officer and President, Branded Pharma at Allergan.( Earlier in his career he held executive roles in sales and marketing at Forest Laboratories, having joined the company in 1993 and advancing through positions in marketing, new products, business development, and sales.( Over his career, he has overseen global commercial organizations managing more than 50 products and $16 billion in revenue, led multiple large pharmaceutical integrations, and been involved in over 20 FDA approvals and numerous new product launches across diverse therapeutic areas.( Meury holds a Bachelor of Arts in Economics from the University of Maryland and has served on several boards, including Syndax Pharmaceuticals and The Jed Foundation.(

Written by Perplexity from public sources.